EU Deja Vu for This Biotech's Orphan Drug

The steady stream of positive news coming from the EU's CHMP today did not extend to Isis Pharmaceuticals and Sanofi . Unfortunately, the duo's drug Kynamro, which is FDA-approved for the treatment of Homozygous Familial Hypercholesterolaemia in the United States, failed to win the green light from the CHMP for the second time.

What does this mean for Isis and Sanofi? And does this make Isis more vulnerable to its competitor Aegerion Pharmaceuticals ? Health-care analyst Max Macaluso dives into these issues in the following video.

What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.

The article EU Deja Vu for This Biotech's Orphan Drug originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.